1: Downes KJ, Cowden C, Laskin BL, Huang YS, Gong W, Bryan M, Fisher BT, Goldstein SL, Zaoutis TE. Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children. JAMA Pediatr. 2017 Dec 4;171(12):e173219. doi: 10.1001/jamapediatrics.2017.3219. Epub 2017 Dec 4. PubMed PMID: 28973124.
2: Castanheira M, Duncan LR, Rhomberg PR, Sader HS. Enhanced activity of cefepime-tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride. Diagn Microbiol Infect Dis. 2017 Dec;89(4):305-309. doi: 10.1016/j.diagmicrobio.2017.08.011. Epub 2017 Aug 24. PubMed PMID: 28969934.
3: Katip W. Visual compatibility of colistin injection with other antibiotics during simulated Y-site administration. Am J Health Syst Pharm. 2017 Jul 15;74(14):1099-1102. doi: 10.2146/ajhp160216. PubMed PMID: 28687555.
4: Ohno Y, Nakamura A, Hashimoto E, Matsutani H, Abe N, Fukuda S, Hisashi K, Komatsu M, Nakamura F. Molecular epidemiology of carbapenemase-producing Enterobacteriaceae in a primary care hospital in Japan, 2010-2013. J Infect Chemother. 2017 Apr;23(4):224-229. doi: 10.1016/j.jiac.2016.12.013. Epub 2017 Feb 1. PubMed PMID: 28161293.
5: Erdman MJ, Riha H, Bode L, Chang JJ, Jones GM. Predictors of Acute Kidney Injury in Neurocritical Care Patients Receiving Continuous Hypertonic Saline. Neurohospitalist. 2017 Jan;7(1):9-14. doi: 10.1177/1941874416665744. Epub 2016 Aug 29. PubMed PMID: 28042364; PubMed Central PMCID: PMC5167096.
6: So W, Kim L, Thabit AK, Nicolau DP, Kuti JL. Physical compatibility of isavuconazonium sulfate with select i.v. drugs during simulated Y-site administration. Am J Health Syst Pharm. 2017 Jan 1;74(1):e55-e63. doi: 10.2146/ajhp150733. Epub 2016 Dec 22. PubMed PMID: 28007722.
7: Thabit AK, Hamada Y, Nicolau DP. Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration. Am J Health Syst Pharm. 2017 Jan 1;74(1):e47-e54. doi: 10.2146/ajhp150762. Epub 2016 Dec 22. Erratum in: Am J Health Syst Pharm. 2017 Apr 1;74(7):457. PubMed PMID: 28007721.
8: Ceftolozane sulfate with tazobactam sodium. Aust Prescr. 2016 Jun;39(3):106-7. doi: 10.18773/austprescr.2016.044. Epub 2016 Apr 18. Review. PubMed PMID: 27346919; PubMed Central PMCID: PMC4919178.
9: Jin H, Qiu F, Ji HJ, Lu Q. Analysis of drug resistance in 1,861 strains of Acinetobacter baumannii. Biomed Rep. 2016 Apr;4(4):463-466. Epub 2016 Feb 15. PubMed PMID: 27073633; PubMed Central PMCID: PMC4812292.
10: Sutherland CA, Nicolau DP. Development of an HPLC Method for the Determination of Ceftolozane/Tazobactam in Biological and Aqueous Matrixes. J Chromatogr Sci. 2016 Jul;54(6):1037-40. doi: 10.1093/chromsci/bmw047. Epub 2016 Apr 4. PubMed PMID: 27048639.
11: Kim TI, Jeong KH, Shin MK, Kim NI. Piperacillin/Tazobactam-Associated Hypersensitivity Syndrome with Overlapping Features of Acute Generalized Exanthematous Pustulosis and Drug-Related Rash with Eosinophilia and Systemic Symptoms Syndrome. Ann Dermatol. 2016 Feb;28(1):98-101. doi: 10.5021/ad.2016.28.1.98. Epub 2016 Jan 28. PubMed PMID: 26848226; PubMed Central PMCID: PMC4737844.
12: O'Donnell JN, Venkatesan N, Manek M, Rhodes NJ, Scheetz MH. Visual and absorbance analyses of admixtures containing vancomycin and piperacillin-tazobactam at commonly used concentrations. Am J Health Syst Pharm. 2016 Feb 15;73(4):241-6. doi: 10.2146/ajhp150170. PubMed PMID: 26843502.
13: Gorlitsky B, El-Ibiary S. A Common But Not so Typical Elevated Anion Gap. Am J Med. 2016 May;129(5):e25-6. doi: 10.1016/j.amjmed.2015.12.021. Epub 2016 Jan 18. PubMed PMID: 26797077.
14: Wade J, Cooper M, Ragan R. Simulated Y-Site Compatibility of Vancomycin and Piperacillin-Tazobactam. Hosp Pharm. 2015 May;50(5):376-9. doi: 10.1310/hpj5005-376. PubMed PMID: 26405323; PubMed Central PMCID: PMC4567203.
15: Al-Attas A, Nasr JJ, El-Enany N, Belal F. A green capillary zone electrophoresis method for the simultaneous determination of piperacillin, tazobactam and cefepime in pharmaceutical formulations and human plasma. Biomed Chromatogr. 2015 Dec;29(12):1811-8. doi: 10.1002/bmc.3500. Epub 2015 Jun 8. PubMed PMID: 26058453.
16: Bošnjak Z, Plecko V, Budimir A, Mareković I, Bedenić B. First Report of NDM-1-Producing Acinetobacter guillouiae. Chemotherapy. 2014;60(4):250-2. doi: 10.1159/000381256. Epub 2015 Apr 25. PubMed PMID: 25925795.
17: Leung E, Venkatesan N, Ly SC, Scheetz MH. Physical compatibility of vancomycin and piperacillin sodium-tazobactam at concentrations typically used during prolonged infusions. Am J Health Syst Pharm. 2013 Jul 1;70(13):1163-6. doi: 10.2146/ajhp120409. PubMed PMID: 23784164.
18: Balaure PC, Andronescu E, Grumezescu AM, Ficai A, Huang KS, Yang CH, Chifiriuc CM, Lin YS. Fabrication, characterization and in vitro profile based interaction with eukaryotic and prokaryotic cells of alginate-chitosan-silica biocomposite. Int J Pharm. 2013 Jan 30;441(1-2):555-61. doi: 10.1016/j.ijpharm.2012.10.045. Epub 2012 Nov 20. PubMed PMID: 23178215.
19: Iorio ML, Cheerharan M, Kaufman SS, Reece-Stremtan S, Boyajian M. Acute liver failure following cleft palate repair: a case of therapeutic acetaminophen toxicity. Cleft Palate Craniofac J. 2013 Nov;50(6):747-50. doi: 10.1597/12-109. Epub 2012 Aug 31. PubMed PMID: 22937760.
20: Jiang R, Sun G. [Determination of target compounds in cefoperazone sodium and tazobactam sodium for injection by capillary electrophoresis]. Se Pu. 2012 Jan;30(1):103-6. Chinese. PubMed PMID: 22667102.